Literature DB >> 12570808

Peptidases, proteases and amyloid beta-peptide catabolism.

Louis B Hersh1.   

Abstract

The formation of senile plaques containing amyloid beta peptides (Abeta peptides) as a major constituent plays a significant role in development of Alzheimer's disease. The concentration of Abeta peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the beta and gamma secretases involved in the synthesis of the Abeta peptides. More recently interest in the mechanism of clearance of the Abeta peptides has emerged, as promoting Abeta peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Abeta peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Abeta peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570808     DOI: 10.2174/1381612033391676

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  12 in total

1.  Insulysin: an allosteric enzyme as a target for Alzheimer's disease.

Authors:  Eun Suk Song; Louis B Hersh
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

2.  Proteolytic fragments of insulysin (IDE) retain substrate binding but lose allosteric regulation.

Authors:  Eun Suk Song; Clint Cady; Michael G Fried; Louis B Hersh
Journal:  Biochemistry       Date:  2006-12-19       Impact factor: 3.162

3.  Human membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40.

Authors:  J Y Huang; A M Bruno; C A Patel; A M Huynh; K D Philibert; M J Glucksman; R A Marr
Journal:  Neuroscience       Date:  2008-05-16       Impact factor: 3.590

Review 4.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10

Review 5.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

6.  Neprilysin regulates amyloid Beta peptide levels.

Authors:  Robert A Marr; Hanjun Guan; Edward Rockenstein; Mark Kindy; Fred H Gage; Inder Verma; Eliezer Masliah; Louis B Hersh
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Authors:  J Steven Jacobsen; Thomas A Comery; Robert L Martone; Hassan Elokdah; David L Crandall; Aram Oganesian; Suzan Aschmies; Yolanda Kirksey; Cathleen Gonzales; Jane Xu; Hua Zhou; Kevin Atchison; Erik Wagner; Margaret M Zaleska; Indranil Das; Robert L Arias; Jonathan Bard; David Riddell; Stephen J Gardell; Magid Abou-Gharbia; Albert Robichaud; Ronald Magolda; George P Vlasuk; Thorir Bjornsson; Peter H Reinhart; Menelas N Pangalos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-16       Impact factor: 11.205

8.  Mammalian pitrilysin: substrate specificity and mitochondrial targeting.

Authors:  K Martin Chow; O Gakh; I C Payne; Maria Aparecida Juliano; Luiz Juliano; G Isaya; Louis B Hersh
Journal:  Biochemistry       Date:  2009-04-07       Impact factor: 3.162

9.  Identification of the allosteric regulatory site of insulysin.

Authors:  Nicholas Noinaj; Sonia K Bhasin; Eun Suk Song; Kirsten E Scoggin; Maria A Juliano; Luiz Juliano; Louis B Hersh; David W Rodgers
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

10.  Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice.

Authors:  Brian Spencer; Robert A Marr; Edward Rockenstein; Leslie Crews; Anthony Adame; Rewati Potkar; Christina Patrick; Fred H Gage; Inder M Verma; Eliezer Masliah
Journal:  BMC Neurosci       Date:  2008-11-12       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.